Clinical trial NCT02111291: Santyl Applications to Diabetic Foot Ulcers
Official title: Clinical Outcomes Associated With Enzymatic Debridement of Diabetic Foot Ulcers for Up To 12 Weeks With Clostridial Collagenase (Santyl®) Ointment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetic Foot Ulcers
Diabetic Foot Wounds
Keywords: Diabetic Foot Ulcers
Lead sponsor: Healthpoint
Sponsor class: INDUSTRY
First posted: 2014-04-11
Enrollment: 215
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current trial examines the potential benefits of continuous 12 week treatment with Santyl, measured in terms of wound bed appearance. The visual appearance of granulation tissue will be recorded at each visit for the purpose of examining the relationship between wound bed appearance and progress towards healing. In support of this longer treatment regimen with Santyl, a recent animal study found that application of Santyl for 12 weeks was safe and well tolerated. Therefore, the present study is designed to test the hypothesis that daily treatment of diabetic foot ulcers (DFU) with Santyl for up to 12 weeks will result in more rapid development of granulation tissue than DFU treated with supportive care.


Eligibility criteria: Inclusion Criteria:

Subjects will be considered qualified for enrollment if they meet the following criteria:

1. Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
2. Eighteen (18) years of age or older, of either sex, and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
3. Willing and able to make all required study visits.
4. Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.
5. Willing to use an appropriate off-loading device whenever necessary to keep weight off of any foot ulcers.
6. An ulcer present on any part of the plantar surface of the foot or plantar surface of the hallux which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit) with a duration ≥ 6 weeks but not more than 52 weeks (12 months) documented in the patient's history or by patient report of onset which requires debridement.
7. Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of \> 0.70 and ≤ 1.20. If ABI \> 1.2, perfusion at or near the site of the ulcer should be confirmed; the foot is warm to the touch and has palpable pulses.
8. Separation of at least 5 cm (closest ulcer edge to other closest ulcer edge) if ≥ 2 ulcers are present.
9. Diabetes mellitus (Type 1 or 2) requiring insulin or oral/injectable medications to control blood glucose levels.
10. Target ulcer is not infected based on clinical assessment.

Exclusion Criteria:

Any one (1) of the following criteria will disqualify a potential Subject from participation in the study.

1. Contraindications or hypersensitivity to the use of clostridial collagenase or hydrogel.
2. Undergoing therapy with another investigational agent within thirty (30) days of Visit 1, or planned participation overlapping with this study.
3. Bleeding disorder that would preclude sharp debridement during the study.
4. Active cellulitis of the target ulcer, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
5. Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).
6. A target ulcer which involves the underlying tissues of tendon, muscle, or bone.
7. Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.
8. Current treatment (at the time of the Screening Visit) with any of the following:

   * Systemic corticosteroids. If corticosteroid treatment was for ≥ 10 days, there must be a 1 week interval between discontinuation and screening.
   * Immunosuppressive agents
   * Chemotherapeutic agents
   * Antiviral agents
   * Systemic antibiotic therapy or topical antibiotic treatment of the target ulcer
9. Treatment of target ulcer with bioactive therapies within 1 month of screening:

   * Platelet-derived growth factor (e.g., Regranex)
   * Living skin equivalent (e.g., Apligraf)
   * Dermal substitute (e.g., Dermagraft, Integra, Oasis, etc.)
10. Treatment of target ulcer for any length of time with clostridial collagenase ointment (SANTYL®) if within 12 weeks prior to screening.
11. Target ulcer that failed to develop well-established granulation tissue when treated with clostridial collagenase ointment (SANTYL®) for at least 4 weeks.
12. Radiation therapy to the target lower extremity within 30 days prior to screening.
13. Medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
14. Blood counts and blood chemistry values as follows:

    * Alanine aminotransferase (ALT) \> 3x upper limit of normal
    * Aspartate aminotransferase (AST) \> 3x upper limit of normal
    * Gamma Glutamyl Transferase (GGT) \> 2.5x upper limit of normal
    * Serum albumin \< 2.0 g/dL • Pre-albumin levels of \< 10 mg/dL
    * Alkaline phosphatase \> 500 U/L • Serum total bilirubin \> 3.0 mg/dL
    * Serum BUN \> 75 mg/dL • Serum creatinine \> 4.5 mg/dL
    * HbA1c \> 12% • Hemoglobin (Hgb) \< 8.0 g/dL
    * WBC \< 2.0 x 109/L • Absolute neutrophil count \< 1.0 x 109/L
    * Platelet count \< 50 x 109/L • INR \> 1.5x upper limit of normal

Furthermore, prior to randomization at Visit 1, the following exclusion criteria will apply:

1. Use of excluded concomitant medications or therapies between Screening and Visit 1.
2. A clinically diagnosed infection of the target ulcer requiring treatment.
3. Muscle, tendon, or bone exposure in the target ulcer.
4. After debridement at Visit 1, the ulcer area is \>12 cm2.

Primary outcomes:
measure: Time to Well-established Granulation Tissue
timeFrame: 12 Weeks
Secondary outcomes:
measure: Adverse Event
timeFrame: 12 Weeks
Other outcomes:
Locations:
city: Mesa
country: United States
state: Arizona
city: Carlsbad
country: United States
state: California
city: Castro Valley
country: United States
state: California
city: Fair Oaks
country: United States
state: California
city: Fresno
country: United States
state: California
city: Sylmar
country: United States
state: California
city: Doral
country: United States
state: Florida
city: Warner Robins
country: United States
state: Georgia
city: Shreveport
country: United States
state: Louisiana
city: Baltimore
country: United States
state: Maryland
city: Kansas City
country: United States
state: Missouri
city: Las Vegas
country: United States
state: Nevada
city: New York
country: United States
state: New York
city: Greenville
country: United States
state: North Carolina
city: Reading
country: United States
state: Pennsylvania
city: York
country: United States
state: Pennsylvania
city: Fort Worth
country: United States
state: Texas
city: McAllen
country: United States
state: Texas
city: Temple
country: United States
state: Texas
city: Saint George
country: United States
state: Utah
city: Roanoke
country: United States
state: Virginia
city: Virginia Beach
country: United States
state: Virginia
city: Calgary
country: Canada
state: Alberta
city: Hamilton
country: Canada
state: Ontario
city: Montreal
country: Canada
state: Quebec
Study officials:
affiliation: Smith and Nephew Biotherapeutics
name: Hebert B Slade, MD
role: STUDY_CHAIR
References: